Journal article · 2020 · Open access

Immunotherapy with DNA vaccine and live attenuated rubella/SIV gag vectors plus early ART can prevent SIVmac251 viral rebound in acutely infected rhesus macaques

Konstantin Virnik, Margherita Rosati, Alexei Medvedev, Aaron Scanlan, Gabrielle Walsh, Frances Dayton, Kate E. Broderick, Mark G. Lewis, Yvonne J. Bryson, Jeffrey D. Lifson, Ruth M. Ruprecht, Barbara K. Felber and 1 more

PLoS ONE, 15(3), e0228163 · Published 4 March 2020 · DOI 10.1371/journal.pone.0228163

Open PDFView at the publisherCite this paper

In brief

“Immunotherapy with DNA vaccine and live attenuated rubella/SIV gag vectors plus early ART can prevent SIVmac251 viral rebound in acutely infected rhesus macaques” is a 2020 journal article by Konstantin Virnik and 12 co-authors, published in PLoS ONE. OpenAlex counts 5 citations as of 19 November 2026. It is open access under a public domain licence: the full text is free to read at PLoS ONE.

Citations
5
Most cited in
2023 (2)
Field-weighted impact
0.47
References
39
Authors
13

Abstract

Anti-retroviral therapy (ART) has been highly successful in controlling HIV replication, reducing viral burden, and preventing both progression to AIDS and viral transmission. Yet, ART alone cannot cure the infection. Even after years of successful therapy, ART withdrawal leads inevitably to viral rebound within a few weeks or months. Our hypothesis: effective therapy must control both the replicating virus pool and the reactivatable latent viral reservoir. To do this, we have combined ART and immunotherapy to attack both viral pools simultaneously. The vaccine regimen consisted of DNA vaccine expressing SIV Gag, followed by a boost with live attenuated rubella/gag vectors. The vectors grow well in rhesus macaques, and they are potent immunogens when used in a prime and boost strategy. We infected rhesus macaques by high dose mucosal challenge with virulent SIVmac251 and waited three days to allow viral dissemination and establishment of a reactivatable viral reservoir before starting ART. While on ART, the control group received control DNA and empty rubella vaccine, while the immunotherapy group received DNA/gag prime, followed by boosts with rubella vectors expressing SIV gag over 27 weeks. Both groups had a vaccine "take" to rubella, and the vaccine group developed antibodies and T cells specific for Gag. Five weeks after the last immunization, we stopped ART and monitored virus rebound. All four control animals eventually had a viral rebound, and two were euthanized for AIDS. One control macaque did not rebound until 2 years after ART release. In contrast, there was only one viral rebound in the vaccine group. Three out of four vaccinees had no viral rebound, even after CD8 depletion, and they remain in drug-free viral remission more than 2.5 years later. The strategy of early ART combined with immunotherapy can produce a sustained SIV remission in macaques and may be relevant for immunotherapy of HIV in humans.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Virnik, K., Rosati, M., Medvedev, A., Scanlan, A., Walsh, G., Dayton, F., Broderick, K. E., Lewis, M. G., Bryson, Y. J., Lifson, J. D., Ruprecht, R. M., Felber, B. K., & Berkower, I. J. (2020). Immunotherapy with DNA vaccine and live attenuated rubella/SIV gag vectors plus early ART can prevent SIVmac251 viral rebound in acutely infected rhesus macaques. PLoS ONE, 15(3), e0228163. https://doi.org/10.1371/journal.pone.0228163

MLA 9

Virnik, Konstantin, et al. “Immunotherapy with DNA vaccine and live attenuated rubella/SIV gag vectors plus early ART can prevent SIVmac251 viral rebound in acutely infected rhesus macaques.” PLoS ONE, vol. 15, no. 3, 2020, p. e0228163. https://doi.org/10.1371/journal.pone.0228163.

Chicago

Virnik, Konstantin, Margherita Rosati, Alexei Medvedev, Aaron Scanlan, Gabrielle Walsh, Frances Dayton, Kate E. Broderick, et al. 2020. “Immunotherapy with DNA vaccine and live attenuated rubella/SIV gag vectors plus early ART can prevent SIVmac251 viral rebound in acutely infected rhesus macaques.” PLoS ONE 15 (3): e0228163. https://doi.org/10.1371/journal.pone.0228163.

Harvard

Virnik, K. et al. (2020) ‘Immunotherapy with DNA vaccine and live attenuated rubella/SIV gag vectors plus early ART can prevent SIVmac251 viral rebound in acutely infected rhesus macaques’, PLoS ONE, 15(3), p. e0228163. doi:10.1371/journal.pone.0228163.

IEEE

K. Virnik et al., “Immunotherapy with DNA vaccine and live attenuated rubella/SIV gag vectors plus early ART can prevent SIVmac251 viral rebound in acutely infected rhesus macaques,” PLoS ONE, vol. 15, no. 3, p. e0228163, 2020, doi: 10.1371/journal.pone.0228163.

BibTeX

@article{virnik2020immunotherapy,
  title     = {{Immunotherapy with DNA vaccine and live attenuated rubella/SIV gag vectors plus early ART can prevent SIVmac251 viral rebound in acutely infected rhesus macaques}},
  author    = {Virnik, Konstantin and Rosati, Margherita and Medvedev, Alexei and Scanlan, Aaron and Walsh, Gabrielle and Dayton, Frances and Broderick, Kate E. and Lewis, Mark G. and Bryson, Yvonne J. and Lifson, Jeffrey D. and Ruprecht, Ruth M. and Felber, Barbara K. and Berkower, Ira J.},
  journal   = {PLoS ONE},
  year      = {2020},
  volume    = {15},
  number    = {3},
  pages     = {e0228163},
  doi       = {10.1371/journal.pone.0228163},
  url       = {https://doi.org/10.1371/journal.pone.0228163}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202011
202111
202211
202322

Its field-weighted citation impact is 0.47: it has been cited 0.47 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment

  • HIV cure
  • SIVmac251
  • viral rebound
  • early antiretroviral therapy
  • DNA vaccine
  • Gag antigen
  • viral reservoir
  • rhesus monkeys

Work with this paper

Most-cited papers in Immunology and Microbiology

All highly cited Immunology and Microbiology papers

Questions about this paper

How do I cite this paper in APA style?

Virnik, K., Rosati, M., Medvedev, A., Scanlan, A., Walsh, G., Dayton, F., Broderick, K. E., Lewis, M. G., Bryson, Y. J., Lifson, J. D., Ruprecht, R. M., Felber, B. K., & Berkower, I. J. (2020). Immunotherapy with DNA vaccine and live attenuated rubella/SIV gag vectors plus early ART can prevent SIVmac251 viral rebound in acutely infected rhesus macaques. PLoS ONE, 15(3), e0228163. https://doi.org/10.1371/journal.pone.0228163

How many times has this paper been cited?

5 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at PLoS ONE: sign in and open the PDF from this page.

Who wrote this paper?

Konstantin Virnik, Margherita Rosati, Alexei Medvedev, Aaron Scanlan, Gabrielle Walsh, Frances Dayton, Kate E. Broderick, Mark G. Lewis, Yvonne J. Bryson, Jeffrey D. Lifson, Ruth M. Ruprecht, Barbara K. Felber and 1 more.

What is the DOI of this paper?

10.1371/journal.pone.0228163, permanently at https://doi.org/10.1371/journal.pone.0228163. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.